TABLE 2.
Groupa | 1st immunization (day 0) | 2nd immunization (day 21) | Challenge (day 35) |
---|---|---|---|
FI-BRSV (i.n./i.n.) | Intranasal | Intranasal | BRSV |
FI-BRSV (i.n./s.c.) | Intranasal | Subcutaneous | BRSV |
FI-BRSV (s.c./i.n.) | Subcutaneous | Intranasal | BRSV |
FI-BRSV (s.c./s.c.) | Subcutaneous | Subcutaneous | BRSV |
Saline-BRSV challenge | Intranasal | Intranasal | BRSV |
Saline-saline | Intranasal | Intranasal | Saline |
FI-BRSV was formulated with 4 μg CpG ODN and 25 μg PP.